CHARM Therapeutics
Last verified 2026-05-13. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-b, $80.0M, 2025-09-02attributed |
| Founded | 2021 |
| Headquarters | London |
| Industry | biotech |
| Stage | series-b+ |
| Website | charmtx.com |
CHARM Therapeutics has developed a menin inhibitor that treats Acute Myeloid Leukemia by reprogramming cancerous cells rather than just killing them. It targets AML patients who develop resistance to existing menin inhibitor treatments. The compound is structurally optimized to bind precisely within the KMT2A interface on menin for more durable resistance results.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-09-02 | series-b | $80.0M | khosla |
Detected tech stack
Nginx, WordPress 7.0, Lenis 1.1.13, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 4.1.4, parallax.js, PHP, Onsen UI, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $80.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Company existence | self-reported | charmtx.com, read 2026-05-13 |
| Description | self-reported | charmtx.com, read 2026-05-13 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.